{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:35:07Z","timestamp":1761129307478},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5697","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T22:08:02Z","timestamp":1456783682000},"page":"467-471","source":"Crossref","is-referenced-by-count":11,"title":["Renal Insufficiency in Concert with Renin-angiotensin-aldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low-dose Trimethoprim-sulfamethoxazole in Adults"],"prefix":"10.2169","volume":"55","author":[{"given":"Kazuhiko","family":"Higashioka","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[{"name":"Clinical Education Center, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Oryoji","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kamada","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Mizuki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Yokota","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342: 1416-1429, 2000.","DOI":"10.1056\/NEJM200005113421907"},{"key":"2","unstructured":"2. Wilkin A, Feinberg J. Pneumocystis carinii pneumonia: a clinical review. Am Fam Physician 60: 1699-1708, 1713-1714, 1999."},{"key":"3","unstructured":"3. Castro M. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Semin Respir Infect 13: 296-303, 1998."},{"key":"4","unstructured":"4. CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. Morb Mortal Wkly Res 38 Suppl 5: 1, 1989."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 297: 1419-1426, 1977.","DOI":"10.1056\/NEJM197712292972602"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 323: 776-782, 1990.","DOI":"10.1056\/NEJM199009203231202"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10: CD005590, 2014.","DOI":"10.1002\/14651858.CD005590.pub3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and\/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Intern Med 42: 665-669, 2003.","DOI":"10.2169\/internalmedicine.42.665"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 119: 296-301, 1993.","DOI":"10.7326\/0003-4819-119-4-199308150-00008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schlanger LE, Kleyman TR, Ling BN. K<sup>+<\/sup>-sparing diuretic actions of trimethoprim: inhibition of Na<sup>+<\/sup> channels in A6 distal nephron cells. Kidney Int 45: 1070-1076, 1994.","DOI":"10.1038\/ki.1994.143"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Perazella MA. Trimethoprim is a potassium-sparing diuretic like amiloride and causes hyperkalemia in high-risk patients. Am J Ther 4: 343-348, 1997.","DOI":"10.1097\/00045391-199709000-00010"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Perazella MA. Trimethoprim-induced hyperkalemia. Clinical data, mechanism, prevention and management. Drug Safety 22: 227-236, 2000.","DOI":"10.2165\/00002018-200022030-00006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 183: 1851-1858, 2011.","DOI":"10.1503\/cmaj.111152"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ingelfinger JR. A new era for the treatment of hyperkalemia? N Engl J Med 372: 275-277, 2015.","DOI":"10.1056\/NEJMe1414112"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Am J Nephrol 19: 389-394, 1999.","DOI":"10.1159\/000013483"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Weir MA, Jurrlink DN, Gomes T, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol 5: 1544-1551, 2010.","DOI":"10.2215\/CJN.01970310"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim\/sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 170: 1045-1049, 2010.","DOI":"10.1001\/archinternmed.2010.142"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalemia in elderly patients receiving spironolactone: nested case-control study. BMJ 343: d5228, 2011.","DOI":"10.1136\/bmj.d5228"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lam N, Weir MA, Juurlink DN, et al. Hospital admissions for hyperkalemia with trimethoprim-sulfamethoxazole: a cohort study using health care database codes for 393,039 older women with urinary tract infections. Am J Kidney Dis 57: 521-523, 2011.","DOI":"10.1053\/j.ajkd.2010.11.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother 47: 1618-1626, 2013.","DOI":"10.1177\/1060028013509973"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ahmed MI, Ekundayo OJ, Mujib M, et al. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol 144: 383-388, 2010.","DOI":"10.1016\/j.ijcard.2009.04.041"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int (in press).","DOI":"10.1038\/ki.2014.382"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 124: 316-320, 1996.","DOI":"10.7326\/0003-4819-124-3-199602010-00006"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 34: 333-339, 2014.","DOI":"10.1016\/j.semnephrol.2014.04.008"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension 53: 754-760, 2009.","DOI":"10.1161\/HYPERTENSIONAHA.108.125252"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Marinella MA. Trimethoprim-induced hyperkalemia: an analysis of reported cases. Gerontology 45: 209-212, 1999.","DOI":"10.1159\/000022089"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Halperin ML, Kamel KS. Potassium. Lancet 352: 135-140, 1998.","DOI":"10.1016\/S0140-6736(98)85044-7"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 58: 2084-2092, 2000.","DOI":"10.1111\/j.1523-1755.2000.00381.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Cremades A, Vicente-Ortega V, Penafiel R. Influence of murine renal sexual dimorphism on amiloride-induced hyperkalemia. Nephron Physiol 95: 57-66, 2003.","DOI":"10.1159\/000074331"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Eiam-ong S, Kurtzman NA, Sabatini A. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 49: 1372-1378, 1996.","DOI":"10.1038\/ki.1996.193"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 99: 57-65, 2005.","DOI":"10.1111\/j.1523-1755.2005.09911.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/5\/55_55.5697\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T07:15:13Z","timestamp":1498288513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/5\/55_55.5697\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5697","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}